The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Abstract
Objective: Etanercept has been shown to improve the articular and cutaneous manifestations of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA. Methods: Patients with PsA (n = 205) were randomized to receive placebo or 25 mg etanercept subcutaneously twice weekly for 24 weeks. Patients continued to receive blind‐labeled therapy in a maintenance phase until all had completed the 24‐week phase, then could receive open‐label etanercept in a 48‐week extension. Efficacy and safety were evaluated at 4, 12, and 24 weeks and at 12‐week intervals thereafter. Radiographs of the hands and wrists were assessed at baseline and 24 weeks, at entry to the open‐label phase, and after 48 weeks in the study. Results: Etanercept significantly reduced the signs and symptoms of PsA and psoriasis. At 12 weeks, 59% of etanercept patients met the American College of Rheumatology 20% improvement criteria for joint response, compared with 15% of placebo patients (P < 0.0001), and results were sustained at 24 and 48 weeks. At 24 weeks, 23% of etanercept patients eligible for psoriasis evaluation achieved at least 75% improvement in the Psoriasis Area and Severity Index, compared with 3% of placebo patients (P = 0.001). Radiographic disease progression was inhibited in the etanercept group at 12 months; the mean annualized rate of change in the modified total Sharp score was −0.03 unit, compared with +1.00 unit in the placebo group (P = 0.0001). Etanercept was well tolerated. Conclusion: Etanercept reduced joint symptoms, improved psoriatic lesions, inhibited radiographic progression, and was well tolerated in patients with PsA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
STEINBROCKER, O. (1949) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1949.02900430001001 · Cited by 2,877
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Radiographic Evaluation of Rheumatoid Arthritis and Related Conditions by Standard Reference Films
Larsen, A., Dale, K., & Eek, M. (1977) · Acta Radiologica. Diagnosis · doi:10.1177/028418517701800415 · Cited by 1,825
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Self-citationEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Self-citationEtanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Self-citation
Cited by
Braun, J., & Sieper, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60635-7 · Cited by 1,806
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O., & Nash, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032482 · Cited by 1,536
Self-citationJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Mease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Self-citationMcInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Self-citationAdverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
Antoni, C., Krueger, G. G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L. T., & Kavanaugh, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032268 · Cited by 715
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationAntoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20967 · Cited by 640
Kavanaugh, A., McInnes, I., Mease, P., Krueger, G. G., Gladman, D., Gomez‐Reino, J., Papp, K., Zrubek, J., Mudivarthy, S., Mack, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24403 · Cited by 602
Self-citationGottlieb, A., Menter, A., Mendelsohn, A., Shen, Y.-K., Li, S., Guzzo, C., Fretzin, S., Kunynetz, R., & Kavanaugh, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60140-9 · Cited by 585
van der Heijde, D., Landewé, R., Einstein, S., Ory, P., Vosse, D., Ni, L., Lin, S. ‐., Tsuji, W., & Davis, J. C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23471 · Cited by 549
Self-citationSingh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40726 · Cited by 493
Self-citationSingh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23789 · Cited by 466
Self-citationKimball, A. B., Gladman, D., Gelfand, J. M., Gordon, K., Horn, E. J., Korman, N. J., Korver, G., Krueger, G. G., Strober, B. E., & Lebwohl, M. G. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.01.006 · Cited by 432
van der Heijde, D., Salonen, D., Weissman, B. N., Landewé, R., Maksymowych, W. P., Kupper, H., Ballal, S., Gibson, E., Wong, R., & the Canadian (M03-606) study group and the ATLAS study group (2009) · Arthritis Research & Therapy · doi:10.1186/ar2794 · Cited by 413
Self-citationNash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405
Self-citationMcGonagle, D., Lories, R. J. U., Tan, A. L., & Benjamin, M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22758 · Cited by 398
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
Self-citationBraun, J., Davis, J., Dougados, M., Sieper, J., van der Linden, S., & van der Heijde, D. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.040758 · Cited by 384
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Psoriatic arthritis: state of the art review
Coates, L. C., & Helliwell, P. S. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-1-65 · Cited by 353
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202646 · Cited by 343
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Kuek, A., Hazleman, B. L., & Östör, A. J. K. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.052688 · Cited by 335
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.719 · Cited by 324
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
Kingsley, G. H., Kowalczyk, A., Taylor, H., Ibrahim, F., Packham, J. C., McHugh, N. J., Mulherin, D. M., Kitas, G. D., Chakravarty, K., Tom, B. D. M., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/kes001 · Cited by 322
Current and future management of psoriasis
Menter, A., & Griffiths, C. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61129-5 · Cited by 321
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Mease, P., van der Heijde, D., Landewé, R., Mpofu, S., Rahman, P., Tahir, H., Singhal, A., Boettcher, E., Navarra, S., Meiser, K., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212687 · Cited by 303
Self-citationMease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30176 · Cited by 300
Self-citationKavanaugh, A., Ritchlin, C., Rahman, P., Puig, L., Gottlieb, A. B., Li, S., Wang, Y., Noonan, L., Brodmerkel, C., Song, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204741 · Cited by 295
Sfikakis, P. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289205 · Cited by 275
S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update
Nast, A., Boehncke, W., Mrowietz, U., Ockenfels, H., Philipp, S., Reich, K., Rosenbach, T., Sammain, A., Schlaeger, M., Sebastian, M., et al. (2012) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07919.x · Cited by 272
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Self-citationAsh, Z., Gaujoux-Viala, C., Gossec, L., Hensor, E. M., FitzGerald, O., Winthrop, K., van der Heijde, D., Emery, P., Smolen, J. S., & Marzo-Ortega, H. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.150995 · Cited by 258
Heiberg, M. S., Koldingsnes, W., Mikkelsen, K., Rødevand, E., Kaufmann, C., Mowinckel, P., & Kvien, T. K. (2008) · Arthritis Care & Research · doi:10.1002/art.23333 · Cited by 256
Fujita, H., Terui, T., Hayama, K., Akiyama, M., Ikeda, S., Mabuchi, T., Ozawa, A., Kanekura, T., Kurosawa, M., Komine, M., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14523 · Cited by 254
The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases
Aletaha, D., & Smolen, J. S. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.005 · Cited by 152
“However, that study showed a very high placebo response, and in subsequent trials of PsA the PsARC showed good discrimination between active drug and placebo [142–147].”
MethodResultInfluentialSozzani, S., Abbracchio, M. P., Annese, V., Danese, S., De Pità, O., De Sarro, G., Maione, S., Olivieri, I., Parodi, A., & Sarzi-Puttini, P. (2014) · Autoimmunity · doi:10.3109/08916934.2014.897333 · Cited by 22
Metadata
- Authors
- Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-07
- Volume
- 50
- Issue
- 7
- Pages
- 2264-2272
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2149168537
- Cited by
- 882
- References
- 30
- FWCI
- 42.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.